Pancreatic duct lavage cytology combined with a cell-block method for patients with possible pancreatic ductal adenocarcinomas, including pancreatic carcinoma in situ
- Author:
Hiroaki KUSUNOSE
1
;
Shinsuke KOSHITA
;
Yoshihide KANNO
;
Takahisa OGAWA
;
Toshitaka SAKAI
;
Keisuke YONAMINE
;
Kazuaki MIYAMOTO
;
Fumisato KOZAKAI
;
Hideyuki ANAN
;
Kazuki ENDO
;
Haruka OKANO
;
Masaya OIKAWA
;
Takashi TSUCHIYA
;
Takashi SAWAI
;
Yutaka NODA
;
Kei ITO
Author Information
- Publication Type:Original Article
- From:Clinical Endoscopy 2023;56(3):353-366
- CountryRepublic of Korea
- Language:English
-
Abstract:
Background/Aims:This study aimed to clarify the efficacy and safety of pancreatic duct lavage cytology combined with a cell-block method (PLC-CB) for possible pancreatic ductal adenocarcinomas (PDACs).
Methods:This study included 41 patients with suspected PDACs who underwent PLC-CB mainly because they were unfit for undergoing endoscopic ultrasonography-guided fine needle aspiration. A 6-Fr double lumen catheter was mainly used to perform PLC-CB. Final diagnoses were obtained from the findings of resected specimens or clinical outcomes during surveillance after PLC-CB.
Results:Histocytological evaluations using PLC-CB were performed in 87.8% (36/41) of the patients. For 31 of the 36 patients, final diagnoses (invasive PDAC, 12; pancreatic carcinoma in situ, 5; benignancy, 14) were made, and the remaining five patients were excluded due to lack of surveillance periods after PLC-CB. For 31 patients, the sensitivity, specificity, and accuracy of PLC-CB for detecting malignancy were 94.1%, 100%, and 96.8%, respectively. In addition, they were 87.5%, 100%, and 94.1%, respectively, in 17 patients without pancreatic masses detectable using endoscopic ultrasonography. Four patients developed postprocedural pancreatitis, which improved with conservative therapy.
Conclusions:PLC-CB has an excellent ability to detect malignancies in patients with possible PDACs, including pancreatic carcinoma in situ.
